In the past year over 250,000 prescriptions for Ovide lotion were filled in the US.
Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF.PK) announced that the US Patent and Trademark Office has issued a patent covering Taro's lice treatment Ovide.
Ovide is based on malathion. The patent is for a highly pure form of malathion for topical pharmaceutical use and a method of making pure pharmaceutical grade malathion, as well as for a formulation containing the pharmaceutical grade malathion and a method for treating head lice.
In the past year over 250,000 prescriptions for Ovide (malathion) lotion, 0.5% were filled in the US, making Ovide the number one prescription treatment for head lice in the US. The American Academy of Pediatrics estimates that between 6 to 12 million Americans are infested with head lice each year, with school children and their families most affected.
Published by Globes [online], Israel business news - www.globes-online.com - on July 15, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009
Hadas Magen and Dan Shohet